Increased CD8+ TIL infiltration, particularly when co-expressing PD-1, has been shown to correlate with improved response to anti-PD-1/PD-L1 therapies in melanoma [11,18,19], underscoring their value as potential biomarkers for treatment stratification. This evidence concerns the gene CD8A and melanoma.